Thursday, April 7th
9:30 - 10:30 Eastern Time
*Please confirm the meeting times in your timezone here*
Within our Member community, access to medicines is a primary focus of concern and it continues to be a key challenge facing people with dermatological conditions. One place that patient advocates can influence the decisions made regarding medicines access is within the Health Technology Assessment review process.
To understand this process in greater depth, Neil Bertelsen, an expert in patient involvement in Health Technology Assessment (HTA) has reviewed the original decision-making processes from several leading HTA bodies when the first new Atopic Eczema biologics were being assessed for reimbursement.
To share his findings and learn about different stakeholder perspectives, GlobalSkin is hosting a virtual panel event Virtual Panel Event: Health Technology Assessment Case Study.
This panel discussion is important to all dermatology conditions as it will examine the issues and potential solutions for improving access to medicines. We invite all Members to attend and learn how HTA bodies make decisions and the impact of the patient voice in the process.
Panel Speakers:
Neil Bertelsen, Neil Bertelsen Consulting
Rachael Manion, Executive Director, Canadian Skin Patient Alliance
Jennifer Austin, CEO, GlobalSkin
Lindsey Smith, Head, Global Public Affairs, Dermatology, Sanofi - on behalf of Sanofi and Regeneron
Register to join us! For more information, please e-mail Stephanie Miller at stephanie.miller@globalskin.org
ON
Canada